Search academic texts

Information × Registration Number 0224U002364, 0123U104369 , R & D reports Title Cytokine-induced killer T cells and bacterial lectins as new biotherapy for breast cancer: an in vitro study popup.stage_title Head Karaman Olha M., Кандидат біологічних наук Registration Date 12-02-2024 Organization R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology National Academy of Sciences of Ukraine popup.description2  The production protocol for obtaining a clinically significant dose of CIК with high functional activity was optimized. A method of CIK viability monitoring was developed by assessing their metabolic activity due to glucose consumption. The obtained cellular product was characterized by a high content of functionally active CD3+CD56+killer lymphocytes (cytotoxic activity) against tumor cells. Lectin B. subtilis IMB B-7724 doesn't cause a toxic effect on human T-lymphocytes and can act as a mitogen. It was first discovered that lectin in human ВС cells activates the apoptotic program in a Caspase 3/7-dependent way. The cytotoxic effect of CIК against MCF-7 and MDA-MB-231 BC cells can be enhanced by incubation with lectin B. subtilis IMВ B-7724. In a 3D model of BC cell culture, it was proven that lectin does not affect the size of spheroids, but prevents the spread of tumor cells. The obtained data show the promise of the combined use of bacterial lectins and cytokine-induced killer T-cells as a new strategy for cancer biotherapy. Product Description popup.authors Voeykova Iryna M. Lykhova Oleksandra O. Cheremshenko Nadiia L. Chekhun Vasyl F. popup.nrat_date 2024-02-12 Close